{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:17:59Z","timestamp":1781342279578,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T00:00:00Z","timestamp":1319587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s11940-011-0151-8","type":"journal-article","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T05:29:30Z","timestamp":1319520570000},"page":"103-112","source":"Crossref","is-referenced-by-count":27,"title":["Treatment of Ocular Myasthenia Gravis"],"prefix":"10.1007","volume":"14","author":[{"given":"Scott R.","family":"Haines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Thurtell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,26]]},"reference":[{"key":"151_CR1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11940-010-0070-0","volume":"12","author":"A Jani-Acsadi","year":"2010","unstructured":"Jani-Acsadi A, Lisak R. Myasthenia gravis. Curr Treat Options Neurol. 2010;12:231\u201343.","journal-title":"Curr Treat Options Neurol"},{"key":"151_CR2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jneuroim.2010.10.020","volume":"231","author":"J Pal","year":"2011","unstructured":"Pal J, Rozsa C, Komoly S et al. Clinical and biological heterogeneity of autoimmune myasthenia gravis. J Neuroimmunol. 2011;231:43\u201354.","journal-title":"J Neuroimmunol"},{"key":"151_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WCO.0b013e3282f4098e","volume":"21","author":"U Luchanok","year":"2008","unstructured":"Luchanok U, Kaminski H. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol. 2008;21:8\u201315.","journal-title":"Curr Opin Neurol"},{"key":"151_CR4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11940-005-0009-z","volume":"7","author":"N Porter","year":"2005","unstructured":"Porter N, Salter B. Ocular myasthenia gravis. Curr Treat Options Neurol. 2005;7:79\u201388.","journal-title":"Curr Treat Options Neurol"},{"key":"151_CR5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","volume":"16","author":"M Benatar","year":"2006","unstructured":"Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16:459\u201367.","journal-title":"Neuromuscul Disord"},{"key":"151_CR6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archopht.1982.01030030765008","volume":"100","author":"N Miller","year":"1982","unstructured":"Miller N, Morris J, Maquire M. Combined use of neostigmine and ocular motility measurements in the diagnosis of myasthenia gravis. Arch Ophthalmol. 1982;100:761\u20133.","journal-title":"Arch Ophthalmol"},{"key":"151_CR7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jocn.2007.09.028","volume":"15","author":"V Zouvelou","year":"2008","unstructured":"Zouvelou V, Potagas C, Karandreas N, et al. Concurrent presentation of ocular myasthenia and euthyroid graves ophthalmopathy: a diagnostic challenge. J Clin Neurosci. 2008;15:718\u201320.","journal-title":"J Clin Neurosci"},{"key":"151_CR8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archneur.1986.00520080081029","volume":"43","author":"B Daroff","year":"1986","unstructured":"Daroff B. The office tensilon test for ocular myasthenia gravis. Arch Neurol. 1986;43:843\u20134.","journal-title":"Arch Neurol"},{"key":"151_CR9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 2009;256:1314\u201320.","journal-title":"J Neurol"},{"key":"151_CR10","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/archneur.64.12.1790","volume":"64","author":"M Gilbert","year":"2007","unstructured":"Gilbert M, De Sousa E, Savino P. Ocular myasthenia gravis treatment: the case against prednisone therapy and thymectomy. Arch Neurol. 2007;64:1790\u20132.","journal-title":"Arch Neurol"},{"key":"151_CR11","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","volume":"68","author":"M Benatar","year":"2007","unstructured":"Benatar M, Kaminski H. Evidence report: the medical treatment of ocular myasthenia (an evidence review). Neurology. 2007;68:2144\u20139.","journal-title":"Neurology"},{"key":"151_CR12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11910-010-0151-1","volume":"11","author":"V Kumar","year":"2011","unstructured":"Kumar V, Kaminski H. Treatment of myasthenia gravis. Curr Neurol Neurosci Rep. 2011;11:89\u201396.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"151_CR13","first-page":"1","volume":"2","author":"M Mehndiratta","year":"2011","unstructured":"Mehndiratta M, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis (review). Cochrane Libr. 2011;2:1\u201316.","journal-title":"Cochrane Libr"},{"key":"151_CR14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1517\/14656560902950619","volume":"10","author":"J Diaz-Manera","year":"2009","unstructured":"Diaz-Manera J, Rojas-Garcia R, Illa I. Treatment strategies for myasthenia gravis. Expert Opin Pharmacother. 2009;10:1329\u201342.","journal-title":"Expert Opin Pharmacother"},{"key":"151_CR15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/SMJ.0b013e3181c81b93","volume":"103","author":"J Finsterer","year":"2010","unstructured":"Finsterer J, Frank M, Krexner E. Low-dose azathioprine effectively suppresses clinical and immunological manifestations of generalized myasthenia. South Med J. 2010;103:182\u20134.","journal-title":"South Med J"},{"key":"151_CR16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"G Skeie","year":"2010","unstructured":"Skeie G, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893\u2013902.","journal-title":"Eur J Neurol"},{"key":"151_CR17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mus.22002","volume":"44","author":"Y Nagane","year":"2011","unstructured":"Nagane Y, Utsugisawa K, Suzuki S, et al. Topical naphazoline in the treatment of myasthenic blepharoptosis. Muscle Nerve. 2011;44:41\u20134.","journal-title":"Muscle Nerve"},{"key":"151_CR18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICU.0b013e328310da18","volume":"19","author":"A Antonio-Santos","year":"2008","unstructured":"Antonio-Santos A, Eggenberger E. Medical treatment options for ocular myasthenia gravis. Curr Opin Ophthalmol. 2008;19:468\u201378.","journal-title":"Curr Opin Ophthalmol"},{"key":"151_CR19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","volume":"76","author":"I Cortese","year":"2011","unstructured":"Cortese I, Chaudry V, So Y, et al. Evidence based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76:294\u2013300.","journal-title":"Neurology"},{"key":"151_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/CND.0b013e3181ff49f3","volume":"12","author":"H Ibrahim","year":"2010","unstructured":"Ibrahim H, Dimachkie M, Shaibani A. A review: the uses of rituximab in neuromuscular diseases. J Clin Neuromuscul Dis. 2010;12:91\u2013102.","journal-title":"J Clin Neuromuscul Dis"},{"key":"151_CR21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Kaminski H, Cutter G, et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68:797\u2013805.","journal-title":"Ann Neurol"},{"key":"151_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11584740-000000000-00000","volume":"31","author":"C Angelini","year":"2011","unstructured":"Angelini C. Diagnosis and management of autoimmune myasthenia gravis. Clin Drug Investig. 2011;31:1\u201314.","journal-title":"Clin Drug Investig"},{"key":"151_CR23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.thorsurg.2010.08.009","volume":"21","author":"M Zielinksi","year":"2011","unstructured":"Zielinksi M. Management of myasthenic patients with thymoma. Thorac Surg Clin. 2011;21:47\u201357.","journal-title":"Thorac Surg Clin"},{"key":"151_CR24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.athoracsur.2010.08.041","volume":"91","author":"Z Chen","year":"2011","unstructured":"Chen Z, Luo H, Peng Y, et al. Comparative clinical features and immune responses after extended thymectomy for myasthenia gravis in patients with atrophic versus hyperplastic thymus. Ann Thorac Surg. 2011;91:212\u20138.","journal-title":"Ann Thorac Surg"},{"key":"151_CR25","first-page":"832","volume":"88","author":"OC Morris","year":"2004","unstructured":"Morris OC, O\u2019Day J. Strabismus surgery in the management of diplopia caused by myasthenia gravis. Br J Ophthalmol. 2004;88:832.","journal-title":"Br J Ophthalmol"},{"key":"151_CR26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00002341-200103000-00005","volume":"17","author":"E Bradley","year":"2001","unstructured":"Bradley E, Bartley G, Chapman K, et al. Surgical correction of blepharoptosis in patients with myasthenia gravis. Ophthal Plast Recons 2001;17:103\u201310.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"151_CR27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clae.2006.03.007","volume":"29","author":"B Evans","year":"2006","unstructured":"Evans B. Orthoptic indications for contact lens wear. Cont Lens Anterior Eye. 2006;29:175\u201381.","journal-title":"Cont Lens Anterior Eye"},{"key":"151_CR28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/ICL.0b013e31817e7d95","volume":"34","author":"M Migneco","year":"2008","unstructured":"Migneco M. Alleviating vertical diplopia through contact lenses without the use of prism. Eye Contact Lens. 2008;34:297\u20138.","journal-title":"Eye Contact Lens"},{"key":"151_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000322497","volume":"65","author":"Y Nagane","year":"2011","unstructured":"Nagane Y, Suzuki S, Suzuki N, et al. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol. 2011;65:16\u201322.","journal-title":"Eur Neurol"},{"key":"151_CR30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1196\/annals.1405.022","volume":"1132","author":"J Sussman","year":"2008","unstructured":"Sussman J, Argov Z, McKee D, et al. Antisense treatment for myasthenia gravis: experience with monarsen. Ann NY Acad Sci. 2008;1132:283\u201390.","journal-title":"Ann NY Acad Sci"},{"key":"151_CR31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00383-010-2837-5","volume":"27","author":"I Hennessey","year":"2011","unstructured":"Hennessey I, Long A, Hughes I, et al. Thymectomy for inducing remission in juvenile myasthenia gravis. Pediatr Surg Int. 2011;27:591\u20134.","journal-title":"Pediatr Surg Int"},{"key":"151_CR32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ajo.2010.05.002","volume":"15","author":"S Pineles","year":"2010","unstructured":"Pineles S, Avery R, Moss H, et al. Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol. 2010;15:453\u20139.","journal-title":"Am J Ophthalmol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-011-0151-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0151-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:57Z","timestamp":1559437017000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-011-0151-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,26]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["151"],"URL":"https:\/\/doi.org\/10.1007\/s11940-011-0151-8","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,26]]}}}